New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Review

(3598) Views  (677) Full article downloads

Authors: Bernhard T Baune

Published Date October 2008 Volume 2008:4(6) Pages 1181 - 1192

DOI: http://dx.doi.org/10.2147/NDT.S3238

Bernhard T Baune

Department of Psychiatry, School of Medicine, James Cook University, Queensland 4811, Australia

Abstract: Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.

Keywords: quetiapine, major depressive disorders, general anxiety disorder, randomized controlled studies, adverse effects

Readers of this article also read: